This is a working overview of cjc-1295, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-05. Anything still debated is marked as such rather than presented as settled.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Backed by the Kampuchean United Front for National Salvation, an organization of Khmer pro-Soviet Communists and Khmer Rouge defectors, Vietnam invaded Cambodia on 22 December 1978. The invasion succeeded in deposing Pol Pot, but the new state struggled to gain international recognition beyond the Soviet Bloc sphere. Despite the international outcry at the Pol Pot regime's gross human rights violations, representatives of the Khmer Rouge were allowed to be seated in the UN General Assembly, with strong support from China, the Western powers, and the member countries of ASEAN. Following the destruction of the Khmer Rouge, the national reconstruction of Cambodia was hampered, and Vietnam suffered a punitive Chinese attack. Although unable to deter Vietnam from ousting Pol Pot, China demonstrated that its Cold War communist adversary, the Soviet Union, was unable to protect its Vietnamese ally. Former U.S. Secretary of State Henry Kissinger wrote that "China succeeded in exposing the limits of...[Soviet] strategic reach" and speculated that the desire to "compensate for their ineffectuality" contributed to the Soviets' decision to intervene in Afghanistan a year later. In the 1973 oil crisis, Organization of Petroleum Exporting Countries (OPEC) cut their petroleum output. This raised oil prices and hurt Western economies, but helped the Soviet Union by generating a huge flow of money from its oil sales.
=== Food waste reduction === Approximately one-third of all food produced globally is wasted. Innovative food tech solutions are being developed to address this issue. For example, Apeel Sciences has developed an edible coating that extends the shelf life of fruits and vegetables, reducing spoilage and waste.
5G cellular network – next-generation cellular networks which began deployment in 2019. Their major advantage is much higher data rates than previous cellular networks, up to 10 Gbps; 100 times faster than the previous cellular technology, 4G LTE. The higher data rates are achieved partly by using higher frequency radio waves, in the higher microwave band 3–6 GHz, and millimeter wave band, around 28 and 39 GHz. Since these frequencies have a shorter range than previous cellphone bands, the cells will be smaller than the cells in previous cellular networks which could be many miles across. Millimeter-wave cells will only be a few blocks long, and instead of a cell base station and antenna tower, they will have many small antennas attached to utility poles and buildings.
=== Gender === Over the last 33 years, a significant decrease in women's happiness leads researchers to believe that men are happier than women. In contrast, a Pew Research Centre survey found that more women are satisfied with their lives than men, overall. Other research has found no gender gap in happiness. Part of these findings could be due to the way men and women differ in calculating their happiness. Women calculate the positive self-esteem, closeness in their relationships and religion. Men calculate positive self-esteem, active leisure and mental control. Therefore, neither men nor women are at greater risk of being less happy than the other. Earlier in life, women are more likely than men to fulfill their goals (material goals and family life aspirations), thereby increasing their life satisfaction and overall happiness. However, it is later in life that men fulfill their goals, are more satisfied with their family life and financial situation and, as a result, their overall happiness surpasses that of women. Possible explanations include the unequal division of labor within the household, or that women experience more variance (more extremes) in emotion but are generally happier. Effects of gender on well-being are paradoxical: men report feeling less happy than women, however, women are more susceptible to depression.
=== Thrombotic disease === Various kits have a 93 to 95% sensitivity (true positive rate). For hospitalized patients, one study found the specificity to be about 50% (related to false positive rate) in the diagnosis of thrombotic disease.
Sources: en.wikipedia.org
The success of the Half-Life series has spurred the creation of several spin-off games for Half-Life 2. Codename Gordon (sometimes called Codename: Gordon) is a two-dimensional Flash sidescroller shooter developed by NuclearVision, and was released over Valve's Steam online delivery system on May 18, 2004, as a promotional game for the then-upcoming Half-Life 2. Characters from Half-Life have appeared in other games. Peggle Extreme, a special edition of Peggle bundled with the PC version of The Orange Box features levels based on Half-Life 2, Team Fortress 2 and Portal. The headcrab is also an unlockable character in Super Meat Boy when bought on Steam. The Headcrab also appeared in an April Fools event in the MMO Vindictus as an event item along with the Crowbar, possibly due to the game being created on the Source Engine as well. In the game Magicka there is a playable character (after the addition of a DLC), which closely resembles the original zombie from the Half-Life universe, equipped with a crowbar. Gordon also appears in Renegade Ops and the headcrab is available as a pet in Torchlight 2. Half-Life has also inspired a number of fan-made mods, some which have gained recognition on their own. Garry's Mod started as a sandbox mode using Half-Life 2 assets but since has become a commercial product and given users the ability to incorporate other assets. Among notable fan-made campaigns is Minerva, which was designed to extend the story from Half-Life 2.
===== UK ===== Depakote Tablets (as in USA) Tablets – Orlept by Wockhardt and Epilim by Sanofi Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi Syrup – Epilim by Sanofi-Aventis Intravenous injection – Epilim Intravenous by Sanofi Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio. Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
The reign of Juan Carlos I as king of Spain began on November 22, 1975, with his accession to the throne following the death of dictator Francisco Franco, who had designated him as successor and Prince of Spain in 1969, and ended on June 19, 2014, with his abdication.
"Hem. Marker study, ADULTS over 16 years;Asc";Hem. Marker examination, ADULTS over 16 years, Ascites fluid;Hematology marker laboratory "Erythrocytes;Asc";"Asc-Erythrocytes; count";Clinical Biochemistry Laboratory "Erythrocytes;Asc";"Asc-Erythrocytes; numberk";, Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Asc";"Asc-Leukocytes(mononuclear); count";Clinical Biochemistry Laboratory "Leukocytes(polynucleus);Asc";"Asc-Leukocytes(polynucleus); count";Clinical Biochemistry Laboratory "Nucleated cells;Asc";"Asc-Nucleated cells; count";Clinical Biochemistry Laboratory "Nucleated cells;Asc";"Asc-Nucleated cells; numberk";Clinical Biochemistry Laboratory "Carbamide;Asc";"Asc-Carbamide; substancek";Clinical Biochemistry Laboratory "Calcium;Asc";"Asc-Calcium(II); substance c.";Clinical Biochemistry Laboratory "Phosphate;Asc";"Asc-Phosphate(P; inorganic); substance";Clinical Biochemistry Laboratory "Triglyceride;Asc";"Asc-Triglyceride; substance";Clinical Biochemistry Laboratory "Bilirubins;Asc";Asc-Bilirubins, substance;Clinical Biochemistry Laboratory "Albumin;Asc";"Asc-Albumin; bulk";Clinical Biochemistry Laboratory "Protein;Asc";"Asc-Protein; mass spec.";Clinical Biochemistry Laboratory "Amylase, pancreatic type;Asc";"Asc-Amylase, pancreatic type;cat.k.";Clinical Biochemistry Laboratory "Lactate dehydro ase;Asc";"Asc-Lactate dehydro ase;.";Clinical Biochemistry Laboratory "Cholesterol;Asc";"Asc-Cholesterol+ester; substance c.";Clinical Biochemistry Laboratory "Ascites group;Asc";"A Alternative list for Ascites fluid analyses: The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on the sample material Ascites fluid.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.